Sep 22, 2025
European Commission Approves Servier's VORANIGO® (vorasidenib) as the First Targeted Therapy for Grade 2 IDH-Mutant Glioma in the EU
Jul 28, 2025
Servier Announces Positive Data from Long-Term Follow-Up Analysis of the Phase 3 AGILE Trial of TIBSOVO® (ivosidenib) in IDH1-mutated Acute Myeloid Leukemia
Jul 25, 2025
Servier Receives Positive CHMP Opinion for VORANIGO® (vorasidenib) for the Treatment of Adults and Adolescents with Grade 2 IDH-mutant Diffuse Glioma
May 28, 2025
Servier Ranked Among Top Companies Across Several Categories in 2024 PatientView Corporate Reputation of Pharma Survey
Jan 09, 2025
Servier Announces Expansion of its Tibsovo (ivosidenib) Development Program Investigating its Safety and Efficacy in Patients Living with IDH1-Mutated Cancers in Both Hematological Malignancies and Solid Tumors
Nov 13, 2024
Servier to Present Data Across its Hematology Portfolio at the 2024 American Society of Hematology (ASH) Annual Meeting
Nov 12, 2024
Servier to Present Data on IDH-mutant Glioma at the 2024 Society for Neuro-Oncology (SNO) Congress
Aug 06, 2024
Servier's VORANIGO® (vorasidenib) Tablets Receives FDA Approval as First Targeted Therapy for Grade 2 IDH-mutant Glioma
May 30, 2024
Servier Initiates Critical Dialogue on AYA Cancer Survivorship at ASCO 2024
May 23, 2024
Servier Highlights Commitment to Improving Cancer Outcomes at ASCO 2024
May 14, 2024
Servier Ranks 1st Across Several Categories in 2023-2024 PatientView U.S. Corporate Reputation Survey
Apr 08, 2024
Servier Data Presented at AACR Underscores Unwavering Dedication to Advancing Oncology R&D
Feb 21, 2024
Servier Receives Regulatory Filing Acceptances from FDA and EMA for Vorasidenib in the Treatment of IDH-Mutant Diffuse Glioma
Feb 20, 2024
FDA and EMA Accept Vorasidenib Regulatory Submissions for the Treatment of IDH-mutant diffuse glioma
Oct 12, 2020
Servier and CureMatch® Launch Their Self-Certified CE-Marked Clinical Decision Support Software, Bionov(TM)
Sep 24, 2020
Servier and MBC BioLabs Announce Winner of the 2020 Servier Golden Ticket
Apr 01, 2020
The Leukemia & Lymphoma Society And Partners Commit $4.5 Million For Blood Cancer Patients Impacted By COVID-19